|
Medpal AI PLC on Monday reported a 16% rise in orders processed in December compared to November, which it said demonstrates the ‘scalability and resilience’ of its automated dispensing infrastructure. The London-based digital health and AI company focused on wellness management said it processed 33,433 prescription orders through its automated pharmacy operations in December. This generated turnover of £325,000 at an average item value of £9.72, up 16% month-on-month from November when the firm processed 28,789 prescriptions. Chief Executive Jason Drummond said he was ‘delighted’ with the ‘continued strong performance’ despite the Christmas period shortening effective trading days. ‘Processing approximately 33,000 prescriptions in December demonstrates the scalability and resilience of our automated dispensing infrastructure,’ he added. Shares in Medpal AI rose 5.0% to 5.25 pence each in London on Monday. In addition, the firm highlighted the US Food & Drug Administration’s approval of Novo Nordisk AS’s Wegovy pill, making it the first oral GLP-1 medication approved for weight management. Drummond expects the approval to be ‘transformative’ for the industry. ‘By removing the barrier of injectable administration, we anticipate significant expansion of the patient population seeking treatment. MedPal.clinic’s AI-first approach positions us to efficiently serve this growing market whilst maintaining the highest standards of clinical safety and patient care,’ the CEO added. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
